France
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.38 (1.30 - 1.44) | 2019 | Modelled | IHME |
1.4 (1.33 - 1.46) | 2018 | Modelled | IHME |
1.42 (1.35 - 1.48) | 2017 | Modelled | IHME |
1.43 (1.36 - 1.49) | 2016 | Modelled | IHME |
1.44 (1.36 - 1.50) | 2015 | Modelled | IHME |
1.45 (1.37 - 1.51) | 2014 | Modelled | IHME |
1.47 (1.40 - 1.53) | 2013 | Modelled | IHME |
1.49 (1.42 - 1.55) | 2012 | Modelled | IHME |
1.51 (1.44 - 1.57) | 2011 | Modelled | IHME |
1.52 (1.45 - 1.59) | 2010 | Modelled | IHME |
1.54 (1.46 - 1.60) | 2009 | Modelled | IHME |
1.55 (1.47 - 1.61) | 2008 | Modelled | IHME |
1.56 (1.48 - 1.63) | 2007 | Modelled | IHME |
1.57 (1.49 - 1.64) | 2006 | Modelled | IHME |
1.59 (1.50 - 1.66) | 2005 | Modelled | IHME |
1.6 (1.51 - 1.67) | 2004 | Modelled | IHME |
1.61 (1.52 - 1.68) | 2003 | Modelled | IHME |
1.62 (1.53 - 1.69) | 2002 | Modelled | IHME |
1.63 (1.54 - 1.70) | 2001 | Modelled | IHME |
1.65 (1.55 - 1.72) | 2000 | Modelled | IHME |
1.66 (1.57 - 1.73) | 1999 | Modelled | IHME |
1.66 (1.58 - 1.74) | 1998 | Modelled | IHME |
1.67 (1.59 - 1.74) | 1997 | Modelled | IHME |
1.68 (1.60 - 1.75) | 1996 | Modelled | IHME |
1.69 (1.60 - 1.76) | 1995 | Modelled | IHME |
1.7 (1.62 - 1.77) | 1994 | Modelled | IHME |
1.71 (1.63 - 1.78) | 1993 | Modelled | IHME |
1.72 (1.64 - 1.79) | 1992 | Modelled | IHME |
1.73 (1.65 - 1.81) | 1991 | Modelled | IHME |
1.75 (1.65 - 1.83) | 1990 | Modelled | IHME |
0.8 (0.70 - 0.90) | 2010 | Survey/reported | Ramiere, 2016 |
0.7 (0.50 - 0.90) | 2004 | Survey/reported | Meffre C , 2010 |
0.02 (0.02 - 0.03) | 2015 | Modelled | WHO |
0.5 (0.40 - 0.70) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
0.7 (0.50 - 0.90) | 2004 | Survey/reported | ECDC |
0.26 (0.25 - 0.27) | 2013 | Modelled | Schweitzer et al, 2015 |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.07 (0.05 - 0.09) | 2019 | Modelled | IHME |
0.07 (0.06 - 0.09) | 2018 | Modelled | IHME |
0.08 (0.06 - 0.10) | 2017 | Modelled | IHME |
0.09 (0.07 - 0.11) | 2016 | Modelled | IHME |
0.1 (0.08 - 0.12) | 2015 | Modelled | IHME |
0.12 (0.09 - 0.14) | 2014 | Modelled | IHME |
0.14 (0.11 - 0.17) | 2013 | Modelled | IHME |
0.16 (0.13 - 0.20) | 2012 | Modelled | IHME |
0.19 (0.15 - 0.24) | 2011 | Modelled | IHME |
0.22 (0.17 - 0.27) | 2010 | Modelled | IHME |
0.24 (0.19 - 0.30) | 2009 | Modelled | IHME |
0.28 (0.22 - 0.34) | 2008 | Modelled | IHME |
0.31 (0.24 - 0.38) | 2007 | Modelled | IHME |
0.33 (0.26 - 0.42) | 2006 | Modelled | IHME |
0.36 (0.27 - 0.45) | 2005 | Modelled | IHME |
0.37 (0.29 - 0.47) | 2004 | Modelled | IHME |
0.39 (0.30 - 0.49) | 2003 | Modelled | IHME |
0.4 (0.32 - 0.51) | 2002 | Modelled | IHME |
0.42 (0.32 - 0.53) | 2001 | Modelled | IHME |
0.43 (0.33 - 0.55) | 2000 | Modelled | IHME |
0.44 (0.34 - 0.56) | 1999 | Modelled | IHME |
0.45 (0.36 - 0.56) | 1998 | Modelled | IHME |
0.46 (0.37 - 0.57) | 1997 | Modelled | IHME |
0.48 (0.37 - 0.59) | 1996 | Modelled | IHME |
0.49 (0.38 - 0.60) | 1995 | Modelled | IHME |
0.51 (0.41 - 0.62) | 1994 | Modelled | IHME |
0.54 (0.43 - 0.65) | 1993 | Modelled | IHME |
0.56 (0.45 - 0.68) | 1992 | Modelled | IHME |
0.59 (0.47 - 0.72) | 1991 | Modelled | IHME |
0.62 (0.49 - 0.77) | 1990 | Modelled | IHME |
0.01 (0.01 - 0.01) | 2015 | Modelled | WHO |
Showing out of
Show more
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.4 (0.70 - 2.40) | 2009 | Survey/reported | Sauvage C et al , 2015 |
Pregnant women
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.8 (0.60 - 0.70) | 2011 | Survey/reported | Richaud-Eyraud E et al, 2015 |
Prisoners
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.6 (0.10 - 2.10) | 2013 | Survey/reported | Corinne B et al, 2015. |
Number of people living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
1,008,180 (953,804 - 1,054,760) | 1990 | Modelled | IHME |
1,005,010 (955,541 - 1,048,420) | 1991 | Modelled | IHME |
1,001,450 (952,465 - 1,043,600) | 1992 | Modelled | IHME |
997,577 (950,801 - 1,038,490) | 1993 | Modelled | IHME |
993,940 (944,378 - 1,035,550) | 1994 | Modelled | IHME |
990,994 (940,827 - 1,034,370) | 1995 | Modelled | IHME |
988,834 (939,412 - 1,030,830) | 1996 | Modelled | IHME |
987,463 (937,909 - 1,029,140) | 1997 | Modelled | IHME |
986,732 (936,426 - 1,029,780) | 1998 | Modelled | IHME |
986,476 (933,473 - 1,029,660) | 1999 | Modelled | IHME |
986,549 (932,139 - 1,030,780) | 2000 | Modelled | IHME |
986,313 (931,266 - 1,028,460) | 2001 | Modelled | IHME |
985,543 (930,994 - 1,027,620) | 2002 | Modelled | IHME |
984,417 (930,411 - 1,026,050) | 2003 | Modelled | IHME |
983,250 (931,005 - 1,026,500) | 2004 | Modelled | IHME |
982,266 (928,226 - 1,025,940) | 2005 | Modelled | IHME |
981,360 (928,420 - 1,022,520) | 2006 | Modelled | IHME |
980,095 (927,550 - 1,021,310) | 2007 | Modelled | IHME |
978,133 (930,716 - 1,018,720) | 2008 | Modelled | IHME |
975,321 (929,454 - 1,016,380) | 2009 | Modelled | IHME |
971,536 (926,181 - 1,012,230) | 2010 | Modelled | IHME |
965,821 (920,869 - 1,006,260) | 2011 | Modelled | IHME |
958,258 (912,495 - 998,452) | 2012 | Modelled | IHME |
950,341 (903,448 - 990,339) | 2013 | Modelled | IHME |
943,505 (893,475 - 983,008) | 2014 | Modelled | IHME |
938,897 (886,495 - 979,282) | 2015 | Modelled | IHME |
937,279 (891,194 - 975,209) | 2016 | Modelled | IHME |
934,894 (888,416 - 972,462) | 2017 | Modelled | IHME |
926,611 (880,953 - 961,335) | 2018 | Modelled | IHME |
912,929 (861,308 - 951,234) | 2019 | Modelled | IHME |
353,000 (291,000 - 443,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
Showing out of
Show more
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
2.64 (1.98 - 3.41) | 2019 | Modelled | IHME |
2.68 (2.03 - 3.47) | 2018 | Modelled | IHME |
2.74 (2.08 - 3.52) | 2017 | Modelled | IHME |
2.76 (2.10 - 3.55) | 2016 | Modelled | IHME |
2.86 (2.20 - 3.67) | 2015 | Modelled | IHME |
2.84 (2.19 - 3.64) | 2014 | Modelled | IHME |
2.91 (2.26 - 3.73) | 2013 | Modelled | IHME |
2.97 (2.30 - 3.80) | 2012 | Modelled | IHME |
3.01 (2.34 - 3.83) | 2011 | Modelled | IHME |
3.06 (2.37 - 3.90) | 2010 | Modelled | IHME |
3.09 (2.39 - 3.90) | 2009 | Modelled | IHME |
3.1 (2.40 - 3.92) | 2008 | Modelled | IHME |
3.12 (2.41 - 3.94) | 2007 | Modelled | IHME |
3.16 (2.44 - 4.01) | 2006 | Modelled | IHME |
3.22 (2.48 - 4.08) | 2005 | Modelled | IHME |
3.28 (2.53 - 4.16) | 2004 | Modelled | IHME |
3.46 (2.65 - 4.38) | 2003 | Modelled | IHME |
3.54 (2.71 - 4.49) | 2002 | Modelled | IHME |
3.6 (2.76 - 4.57) | 2001 | Modelled | IHME |
3.65 (2.80 - 4.63) | 2000 | Modelled | IHME |
3.72 (2.87 - 4.74) | 1999 | Modelled | IHME |
3.73 (2.88 - 4.76) | 1998 | Modelled | IHME |
3.68 (2.84 - 4.70) | 1997 | Modelled | IHME |
3.67 (2.83 - 4.62) | 1996 | Modelled | IHME |
3.62 (2.80 - 4.56) | 1995 | Modelled | IHME |
3.58 (2.75 - 4.54) | 1994 | Modelled | IHME |
3.54 (2.72 - 4.51) | 1993 | Modelled | IHME |
3.5 (2.68 - 4.50) | 1992 | Modelled | IHME |
3.5 (2.66 - 4.52) | 1991 | Modelled | IHME |
3.52 (2.66 - 4.54) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
1,750 (1,314 - 2,259) | 2019 | Modelled | IHME |
1,770 (1,341 - 2,288) | 2018 | Modelled | IHME |
1,802 (1,371 - 2,316) | 2017 | Modelled | IHME |
1,808 (1,377 - 2,331) | 2016 | Modelled | IHME |
1,867 (1,435 - 2,401) | 2015 | Modelled | IHME |
1,850 (1,428 - 2,367) | 2014 | Modelled | IHME |
1,886 (1,460 - 2,413) | 2013 | Modelled | IHME |
1,916 (1,482 - 2,446) | 2012 | Modelled | IHME |
1,932 (1,499 - 2,458) | 2011 | Modelled | IHME |
1,952 (1,512 - 2,488) | 2010 | Modelled | IHME |
1,959 (1,516 - 2,476) | 2009 | Modelled | IHME |
1,959 (1,518 - 2,476) | 2008 | Modelled | IHME |
1,956 (1,513 - 2,474) | 2007 | Modelled | IHME |
1,969 (1,521 - 2,500) | 2006 | Modelled | IHME |
1,993 (1,534 - 2,527) | 2005 | Modelled | IHME |
2,016 (1,559 - 2,557) | 2004 | Modelled | IHME |
2,112 (1,622 - 2,679) | 2003 | Modelled | IHME |
2,150 (1,646 - 2,724) | 2002 | Modelled | IHME |
2,174 (1,667 - 2,756) | 2001 | Modelled | IHME |
2,186 (1,677 - 2,775) | 2000 | Modelled | IHME |
2,219 (1,711 - 2,827) | 1999 | Modelled | IHME |
2,215 (1,710 - 2,821) | 1998 | Modelled | IHME |
2,171 (1,677 - 2,778) | 1997 | Modelled | IHME |
2,158 (1,665 - 2,719) | 1996 | Modelled | IHME |
2,125 (1,643 - 2,677) | 1995 | Modelled | IHME |
2,093 (1,608 - 2,655) | 1994 | Modelled | IHME |
2,067 (1,589 - 2,632) | 1993 | Modelled | IHME |
2,035 (1,556 - 2,619) | 1992 | Modelled | IHME |
2,029 (1,544 - 2,624) | 1991 | Modelled | IHME |
2,031 (1,536 - 2,625) | 1990 | Modelled | IHME |
3,845 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
12 (8 - 17) | 2019 | Modelled | IHME |
12 (8 - 17) | 2018 | Modelled | IHME |
12 (8 - 17) | 2017 | Modelled | IHME |
12 (8 - 17) | 2016 | Modelled | IHME |
12 (8 - 17) | 2015 | Modelled | IHME |
12 (8 - 17) | 2014 | Modelled | IHME |
12 (8 - 17) | 2013 | Modelled | IHME |
12 (8 - 17) | 2012 | Modelled | IHME |
12 (8 - 17) | 2011 | Modelled | IHME |
12 (8 - 17) | 2010 | Modelled | IHME |
12 (8 - 17) | 2009 | Modelled | IHME |
12 (9 - 17) | 2008 | Modelled | IHME |
12 (9 - 17) | 2007 | Modelled | IHME |
12 (9 - 18) | 2006 | Modelled | IHME |
12 (9 - 18) | 2005 | Modelled | IHME |
12 (9 - 18) | 2004 | Modelled | IHME |
12 (9 - 18) | 2003 | Modelled | IHME |
12 (9 - 18) | 2002 | Modelled | IHME |
13 (9 - 18) | 2001 | Modelled | IHME |
13 (9 - 18) | 2000 | Modelled | IHME |
13 (9 - 18) | 1999 | Modelled | IHME |
13 (9 - 18) | 1998 | Modelled | IHME |
13 (9 - 18) | 1997 | Modelled | IHME |
13 (9 - 18) | 1996 | Modelled | IHME |
13 (9 - 19) | 1995 | Modelled | IHME |
13 (9 - 19) | 1994 | Modelled | IHME |
13 (9 - 19) | 1993 | Modelled | IHME |
13 (9 - 19) | 1992 | Modelled | IHME |
13 (9 - 19) | 1991 | Modelled | IHME |
13 (9 - 19) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
90 | 2018 | Survey/reported | WHO/UNICEF |
90 | 2017 | Survey/reported | WHO/UNICEF |
90 | 2016 | Survey/reported | WHO/UNICEF |
88 | 2015 | Survey/reported | WHO/UNICEF |
83 | 2014 | Survey/reported | WHO/UNICEF |
82 | 2013 | Survey/reported | WHO/UNICEF |
78 | 2012 | Survey/reported | WHO/UNICEF |
74 | 2011 | Survey/reported | WHO/UNICEF |
64 | 2010 | Survey/reported | WHO/UNICEF |
51 | 2009 | Survey/reported | WHO/UNICEF |
47 | 2008 | Survey/reported | WHO/UNICEF |
42 | 2007 | Survey/reported | WHO/UNICEF |
39 | 2006 | Survey/reported | WHO/UNICEF |
35 | 2005 | Survey/reported | WHO/UNICEF |
35 | 2004 | Survey/reported | WHO/UNICEF |
28 | 2003 | Survey/reported | WHO/UNICEF |
29 | 2002 | Survey/reported | WHO/UNICEF |
28 | 2001 | Survey/reported | WHO/UNICEF |
26 | 2000 | Survey/reported | WHO/UNICEF |
24 | 1999 | Survey/reported | WHO/UNICEF |
27 | 1998 | Survey/reported | WHO/UNICEF |
91 | 2019 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
109 | 2015 | Survey/reported | EMCDDA, 2019 |
150 (127 - 186) | 2014 | Survey/reported | EMCDDA, 2017 |
109 | 2015 | Survey/reported | ECDC |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
85 | 2017 | Survey/reported | EMCDDA, 2019 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.85 (0.70 - 1.04) | 2019 | Modelled | IHME |
0.85 (0.69 - 1.03) | 2018 | Modelled | IHME |
0.84 (0.69 - 1.03) | 2017 | Modelled | IHME |
0.84 (0.69 - 1.02) | 2016 | Modelled | IHME |
0.84 (0.68 - 1.03) | 2015 | Modelled | IHME |
0.84 (0.68 - 1.03) | 2014 | Modelled | IHME |
0.84 (0.68 - 1.03) | 2013 | Modelled | IHME |
0.84 (0.69 - 1.03) | 2012 | Modelled | IHME |
0.84 (0.69 - 1.03) | 2011 | Modelled | IHME |
0.84 (0.69 - 1.04) | 2010 | Modelled | IHME |
0.83 (0.68 - 1.01) | 2009 | Modelled | IHME |
0.8 (0.65 - 0.96) | 2008 | Modelled | IHME |
0.75 (0.62 - 0.90) | 2007 | Modelled | IHME |
0.71 (0.59 - 0.85) | 2006 | Modelled | IHME |
0.69 (0.57 - 0.83) | 2005 | Modelled | IHME |
0.68 (0.57 - 0.82) | 2004 | Modelled | IHME |
0.67 (0.56 - 0.81) | 2003 | Modelled | IHME |
0.67 (0.56 - 0.80) | 2002 | Modelled | IHME |
0.66 (0.55 - 0.80) | 2001 | Modelled | IHME |
0.66 (0.55 - 0.80) | 2000 | Modelled | IHME |
0.67 (0.56 - 0.81) | 1999 | Modelled | IHME |
0.68 (0.57 - 0.83) | 1998 | Modelled | IHME |
0.7 (0.58 - 0.86) | 1997 | Modelled | IHME |
0.72 (0.59 - 0.88) | 1996 | Modelled | IHME |
0.74 (0.60 - 0.89) | 1995 | Modelled | IHME |
0.74 (0.61 - 0.90) | 1994 | Modelled | IHME |
0.75 (0.62 - 0.90) | 1993 | Modelled | IHME |
0.75 (0.62 - 0.91) | 1992 | Modelled | IHME |
0.75 (0.62 - 0.91) | 1991 | Modelled | IHME |
0.76 (0.62 - 0.92) | 1990 | Modelled | IHME |
0.3 (0.10 - 0.30) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.17 (0.08 - 0.20) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1 (0.90 - 1.20) | 2010 | Survey/reported | Ramiere, 2016 |
0.84 (0.65 - 1.10) | 2004 | Survey/reported | Meffre C et al, 2010 |
0.6 (0.40 - 1.10) | 2014 | Modelled | Gower et al, 2014 |
0.84 | 2019 | Modelled | Jin et al. 2017 |
0.84 (0.80 - 1.10) | 2004 | Survey/reported | ECDC |
Showing out of
Show more
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1 (0.50 - 1.90) | 2009 | Survey/reported | Sauvage C et al , 2015 |
4.2 | 2019 | Modelled | Jin et al. 2017 |
Showing out of
Show more
Men who have sex with men (MSM) Living with HIV
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
5.6 (4 - 7.50) | 2019 | Modelled | Jin et al. 2017 |
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
62.2 (59.40 - 64.90) | 2011 | Survey/reported | Weill-Barillet L et al, 2016 |
Number of people living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
436,706 (355,338 - 529,133) | 1990 | Modelled | IHME |
437,680 (358,620 - 527,590) | 1991 | Modelled | IHME |
437,285 (359,830 - 526,520) | 1992 | Modelled | IHME |
435,774 (359,708 - 526,691) | 1993 | Modelled | IHME |
433,617 (355,122 - 524,795) | 1994 | Modelled | IHME |
431,246 (350,366 - 524,710) | 1995 | Modelled | IHME |
425,717 (349,594 - 516,940) | 1996 | Modelled | IHME |
416,128 (344,568 - 505,262) | 1997 | Modelled | IHME |
405,796 (337,661 - 489,953) | 1998 | Modelled | IHME |
398,076 (331,263 - 482,823) | 1999 | Modelled | IHME |
396,399 (329,407 - 479,670) | 2000 | Modelled | IHME |
399,846 (331,067 - 482,323) | 2001 | Modelled | IHME |
405,056 (338,121 - 487,591) | 2002 | Modelled | IHME |
411,739 (343,204 - 493,596) | 2003 | Modelled | IHME |
419,655 (348,808 - 502,364) | 2004 | Modelled | IHME |
428,517 (354,683 - 514,931) | 2005 | Modelled | IHME |
445,363 (370,318 - 531,410) | 2006 | Modelled | IHME |
472,486 (392,080 - 565,774) | 2007 | Modelled | IHME |
502,277 (413,320 - 606,158) | 2008 | Modelled | IHME |
527,022 (431,105 - 642,155) | 2009 | Modelled | IHME |
538,874 (441,258 - 663,432) | 2010 | Modelled | IHME |
540,990 (443,797 - 663,522) | 2011 | Modelled | IHME |
542,194 (442,617 - 664,235) | 2012 | Modelled | IHME |
543,075 (442,817 - 667,587) | 2013 | Modelled | IHME |
544,184 (444,590 - 668,016) | 2014 | Modelled | IHME |
545,898 (443,864 - 672,139) | 2015 | Modelled | IHME |
549,138 (449,329 - 672,277) | 2016 | Modelled | IHME |
553,199 (451,427 - 678,250) | 2017 | Modelled | IHME |
558,240 (457,645 - 678,288) | 2018 | Modelled | IHME |
564,899 (464,402 - 691,765) | 2019 | Modelled | IHME |
194,000 (93,000 - 222,000) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue | Year | Type | Source |
---|---|---|---|
24,200 (11,500 - 27,600) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
8.09 (6.60 - 9.63) | 2019 | Modelled | IHME |
8.11 (6.62 - 9.64) | 2018 | Modelled | IHME |
8.15 (6.63 - 9.73) | 2017 | Modelled | IHME |
8.06 (6.56 - 9.60) | 2016 | Modelled | IHME |
8.17 (6.60 - 9.74) | 2015 | Modelled | IHME |
8.04 (6.51 - 9.53) | 2014 | Modelled | IHME |
8.12 (6.66 - 9.64) | 2013 | Modelled | IHME |
8.16 (6.68 - 9.77) | 2012 | Modelled | IHME |
8.14 (6.65 - 9.77) | 2011 | Modelled | IHME |
8.11 (6.62 - 9.74) | 2010 | Modelled | IHME |
8.03 (6.57 - 9.68) | 2009 | Modelled | IHME |
7.93 (6.47 - 9.58) | 2008 | Modelled | IHME |
7.79 (6.40 - 9.41) | 2007 | Modelled | IHME |
7.72 (6.33 - 9.35) | 2006 | Modelled | IHME |
7.71 (6.29 - 9.34) | 2005 | Modelled | IHME |
7.68 (6.28 - 9.31) | 2004 | Modelled | IHME |
7.86 (6.50 - 9.54) | 2003 | Modelled | IHME |
7.85 (6.44 - 9.54) | 2002 | Modelled | IHME |
7.82 (6.40 - 9.52) | 2001 | Modelled | IHME |
7.83 (6.40 - 9.50) | 2000 | Modelled | IHME |
7.97 (6.52 - 9.69) | 1999 | Modelled | IHME |
7.92 (6.45 - 9.69) | 1998 | Modelled | IHME |
7.75 (6.28 - 9.49) | 1997 | Modelled | IHME |
7.66 (6.18 - 9.36) | 1996 | Modelled | IHME |
7.48 (6.02 - 9.11) | 1995 | Modelled | IHME |
7.31 (5.88 - 8.87) | 1994 | Modelled | IHME |
7.11 (5.73 - 8.65) | 1993 | Modelled | IHME |
6.92 (5.58 - 8.46) | 1992 | Modelled | IHME |
6.82 (5.50 - 8.38) | 1991 | Modelled | IHME |
6.75 (5.42 - 8.34) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
5,356 (4,369 - 6,375) | 2019 | Modelled | IHME |
5,353 (4,373 - 6,365) | 2018 | Modelled | IHME |
5,367 (4,363 - 6,406) | 2017 | Modelled | IHME |
5,287 (4,304 - 6,294) | 2016 | Modelled | IHME |
5,340 (4,315 - 6,367) | 2015 | Modelled | IHME |
5,228 (4,237 - 6,199) | 2014 | Modelled | IHME |
5,260 (4,314 - 6,244) | 2013 | Modelled | IHME |
5,261 (4,306 - 6,293) | 2012 | Modelled | IHME |
5,221 (4,261 - 6,265) | 2011 | Modelled | IHME |
5,175 (4,225 - 6,216) | 2010 | Modelled | IHME |
5,096 (4,168 - 6,144) | 2009 | Modelled | IHME |
5,008 (4,087 - 6,051) | 2008 | Modelled | IHME |
4,890 (4,019 - 5,906) | 2007 | Modelled | IHME |
4,814 (3,950 - 5,833) | 2006 | Modelled | IHME |
4,777 (3,895 - 5,783) | 2005 | Modelled | IHME |
4,726 (3,865 - 5,731) | 2004 | Modelled | IHME |
4,804 (3,972 - 5,830) | 2003 | Modelled | IHME |
4,764 (3,910 - 5,790) | 2002 | Modelled | IHME |
4,715 (3,861 - 5,741) | 2001 | Modelled | IHME |
4,692 (3,835 - 5,696) | 2000 | Modelled | IHME |
4,748 (3,883 - 5,773) | 1999 | Modelled | IHME |
4,695 (3,828 - 5,749) | 1998 | Modelled | IHME |
4,580 (3,711 - 5,604) | 1997 | Modelled | IHME |
4,506 (3,636 - 5,506) | 1996 | Modelled | IHME |
4,385 (3,528 - 5,343) | 1995 | Modelled | IHME |
4,275 (3,440 - 5,189) | 1994 | Modelled | IHME |
4,147 (3,340 - 5,045) | 1993 | Modelled | IHME |
4,026 (3,246 - 4,923) | 1992 | Modelled | IHME |
3,954 (3,188 - 4,857) | 1991 | Modelled | IHME |
3,901 (3,132 - 4,820) | 1990 | Modelled | IHME |
4,917 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
45 (35 - 55) | 2019 | Modelled | IHME |
46 (36 - 55) | 2018 | Modelled | IHME |
46 (36 - 56) | 2017 | Modelled | IHME |
46 (36 - 55) | 2016 | Modelled | IHME |
46 (36 - 56) | 2015 | Modelled | IHME |
46 (36 - 55) | 2014 | Modelled | IHME |
45 (36 - 55) | 2013 | Modelled | IHME |
45 (36 - 55) | 2012 | Modelled | IHME |
45 (36 - 55) | 2011 | Modelled | IHME |
45 (35 - 55) | 2010 | Modelled | IHME |
45 (35 - 55) | 2009 | Modelled | IHME |
45 (35 - 55) | 2008 | Modelled | IHME |
44 (34 - 54) | 2007 | Modelled | IHME |
44 (34 - 54) | 2006 | Modelled | IHME |
44 (33 - 54) | 2005 | Modelled | IHME |
43 (33 - 54) | 2004 | Modelled | IHME |
43 (33 - 53) | 2003 | Modelled | IHME |
43 (32 - 53) | 2002 | Modelled | IHME |
42 (32 - 53) | 2001 | Modelled | IHME |
42 (32 - 53) | 2000 | Modelled | IHME |
42 (32 - 52) | 1999 | Modelled | IHME |
42 (32 - 52) | 1998 | Modelled | IHME |
42 (32 - 52) | 1997 | Modelled | IHME |
42 (31 - 52) | 1996 | Modelled | IHME |
42 (31 - 52) | 1995 | Modelled | IHME |
41 (31 - 52) | 1994 | Modelled | IHME |
41 (31 - 52) | 1993 | Modelled | IHME |
41 (31 - 51) | 1992 | Modelled | IHME |
40 (31 - 51) | 1991 | Modelled | IHME |
40 (30 - 51) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
109 | 2015 | Survey/reported | EMCDDA, 2019 |
150 (127 - 186) | 2014 | Survey/reported | EMCDDA, 2017 |
109 | 2015 | Survey/reported | ECDC |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
85 | 2017 | Survey/reported | EMCDDA, 2019 |
Number of persons treated for HCV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
17,325 | 2017 | Survey/reported | ECDC, 2019 |
17,325 | 2017 | Survey/reported | The European Centre for Disease Prevention and Control, 2019 |
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
Hepatitis related deaths (national)
Prevalence < 5
HBV
0.07
(%)
2019, latest modelled
(0.05 - 0.09(%))
IHME
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines